- Investing Ideas
- Hong Kong Pharmaceuticals & Biotech Pure Equity Growth
Hong Kong Pharmaceuticals & Biotech Pure Equity Growth
Results
6
Companies that has zero debt on their balance sheet and is forecast to grow at an exponential rate in the future.
6 companies
Sichuan Kelun-Biotech Biopharmaceutical
Market Cap: HK$120.5b
A biopharmaceutical company, engages in the research and development, manufacturing, and commercialization of novel drugs in oncology, immunology, metabolism, and other therapeutic areas in the People’s Republic of China and internationally.
6990
HK$504.00
7D
-3.7%
1Y
47.0%
Sichuan Kelun-Biotech Biopharmaceutical
Market Cap: HK$120.5b
A biopharmaceutical company, engages in the research and development, manufacturing, and commercialization of novel drugs in oncology, immunology, metabolism, and other therapeutic areas in the People’s Republic of China and internationally.
6990
HK$504.00
7D
-3.7%
1Y
47.0%
Sichuan Kelun-Biotech Biopharmaceutical
Market Cap: HK$120.5b
A biopharmaceutical company, engages in the research and development, manufacturing, and commercialization of novel drugs in oncology, immunology, metabolism, and other therapeutic areas in the People’s Republic of China and internationally.
6990
HK$504.00
7D
-3.7%
1Y
47.0%
CARsgen Therapeutics Holdings
Market Cap: HK$9.1b
An investment holding company, engages in discovering, developing, and commercializing chimeric antigen receptor T (CAR-T) cell therapies for the treatment of hematological malignancies, solid tumors, and autoimmune diseases in China.
2171
HK$15.38
7D
-3.9%
1Y
-26.1%
CARsgen Therapeutics Holdings
Market Cap: HK$9.1b
An investment holding company, engages in discovering, developing, and commercializing chimeric antigen receptor T (CAR-T) cell therapies for the treatment of hematological malignancies, solid tumors, and autoimmune diseases in China.
2171
HK$15.38
7D
-3.9%
1Y
n/a
CARsgen Therapeutics Holdings
Market Cap: HK$9.1b
An investment holding company, engages in discovering, developing, and commercializing chimeric antigen receptor T (CAR-T) cell therapies for the treatment of hematological malignancies, solid tumors, and autoimmune diseases in China.
2171
HK$15.38
7D
-3.9%
1Y
n/a